Latest Europe News

Reliance Worldwide Corporation reported a 4.6% revenue decline and a 34.9% drop in net profit for H1 FY2026, citing US tariffs and weaker demand in key markets. The company balances challenges with cost savings and a shareholder-friendly capital return strategy.

Qualitas Limited reports robust interim results for the six months to December 2025, driven by strong deployment and expanding investor mandates, reaffirming its FY26 guidance.

European Resources Limited has reported encouraging preliminary metallurgical test results for its Korsnäs Rare Earth Element Project in Finland, highlighting significant grade uplift and recovery improvements. These findings mark a key step in advancing the project’s processing flowsheet and strategic positioning within the EU rare earth supply chain.

Osmond Resources is advancing downstream processing opportunities for rare earths, rutile, and silicon at its Orión project in Spain, aiming to leverage strong grades and scale to capture additional value and funding.

AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.

GQG Partners delivered solid full-year 2025 results, with funds under management climbing 7.1% to US$163.9 billion and net income increasing 7.3% to US$463.3 million, despite net outflows. The firm maintained a strong dividend payout, reflecting confidence in its sustainable growth strategy.

Cochlear Limited reported a modest 1% rise in HY26 sales revenue to $1.176 billion, but underlying net profit fell 9% amid slower-than-expected contract renewals for its new Nucleus Nexa implant system. The company anticipates a stronger second half and maintains full-year guidance at the lower end of its forecast.

Cochlear Limited reported a modest 1% rise in sales but a 9% fall in underlying net profit for the half year ended December 2025, as the rollout of its innovative Nucleus Nexa System faced longer-than-expected regulatory and contract hurdles. The company anticipates a robust second half driven by broader product availability and service growth.

Cochlear Limited posted a modest 1% increase in sales revenue for the half year ending December 2025, while underlying net profit fell 9%, impacted by cloud computing costs and a slower-than-expected Nexa System rollout. The company maintains its dividend and outlines cautious FY26 guidance.

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

Savana Asset Management highlights the US as the leading global equity market, driven by robust economic growth, AI investment surges, and investor-friendly policies. Their insights reveal why Australian investors might look across the Pacific for growth opportunities.

Pro Medicus Limited reported a robust half-year performance, with underlying profit after tax rising by approximately 30%, driven by significant new sales and strategic implementations. The company remains confident in its proprietary technology's resilience against AI disruption while expanding its market footprint.